

March 5, 2020

Ono Pharmaceutical Co., Ltd.

**ONO and Nichi-Iko Enter into Licensing Agreement and
Technical Collaboration for Limaprost Alfadex Tablets**

Nichi-Iko Pharmaceutical Co., Ltd. (Toyama, Japan; President and CEO: Yuichi Tamura, “Nichi-Iko”) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director: Gyo Sagara; “ONO”) announced that the Companies have entered into the license agreement including patents, and technical collaboration on Opalmon® (generic name: limaprost alfadex) Tablet 5 µg, an oral Prostaglandin E₁ analogue, manufactured and marketed by ONO in Japan.

Nichi-Iko will convert the formulation of “Limaprost Alfadex tablets 5 µg (Nichiiko)”, currently manufactured and marketed by Nichi-Iko, to a formulation which has been improved for moisture resistance stability following the technology transfer based on patents owned by ONO. After receiving an approval for this improved formulation change, for a partial change in approved items of the manufacturing and marketing approval, Nichi-Iko will manufacture and market the improved formulation in bulk packaging standards through this technical collaboration.

Ono will continue to manufacture and market Opalmon® Tablet 5 µg.

Contacts	
Ono Pharmaceutical Co., Ltd. Corporate Communications public_relations@ono.co.jp	Nichi-Iko Pharmaceutical Co., Ltd. President Office Corporate Communication Department TEL: +81-(0)76-442-7026